The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | How can POLE mutations guide personalized immunotherapy in GI cancers?
Umair Mahmood, BSc, MSc, University College London Hospital, London, UK, comments on the biological and clinical implications of POLE mutations as potential predictive biomarkers for immune checkpoint inhibitor therapy in gastrointestinal cancers. Both exonuclease domain and non-exonuclease domain POLE variants were associated with durable responses in this case series, supporting their potential role in patient selection. Liquid biopsy, multidisciplinary decision-making, and individualized treatment strategies are needed to optimize immunotherapy duration and surgical management in this rare molecular subgroup. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
